Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 0 | 261 | 123 | 3,101 | 699 |
| Gross Profit | N/A | 261 | 123 | 3,101 | 699 |
| Operating Expenses | 28,589 | 20,350 | 18,252 | 17,867 | 3,517 |
| Operating Income | -28,589 | -20,090 | -18,129 | -14,766 | -2,819 |
| Interest Expense | 0 | 0 | 0 | 0 | 29 |
| Other Income | 1,069 | 1,061 | 74 | -20 | 0 |
| Pre-tax Income | -27,520 | -19,029 | -18,054 | -14,786 | -2,848 |
| Net Income Continuous | -27,520 | -19,029 | -18,054 | -14,786 | -2,848 |
| Net Income | $-27,520 | $-19,029 | $-18,054 | $-14,786 | $-2,848 |
| EPS Basic Total Ops | -1.16 | -3.16 | -4.28 | -4.86 | -2.10 |
| EPS Basic Continuous Ops | -1.16 | -3.16 | -4.28 | -4.87 | -2.08 |
| EPS Diluted Total Ops | -1.16 | -3.16 | -4.28 | -4.86 | -2.10 |
| EPS Diluted Continuous Ops | -1.16 | -3.16 | -4.28 | -4.87 | -2.08 |
| EPS Diluted Before Non-Recurring Items | -1.16 | -3.57 | -4.32 | -4.86 | -2.10 |
| EBITDA(a) | $-28,563 | $-19,912 | $-18,122 | $-14,766 | $-2,819 |